+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the safety and effectiveness of the FloStent, a medical device used for treating men experiencing symptoms of Benign Prostatic Hyperplasia BPH. The study compares the FloStent implant procedure to a sham procedure without deploying the device. It involves men aged 45 and older with symptomatic BPH to better understand how this device may impact urinary symptoms. Participants will undergo a flexible cystoscopy procedure. Those randomized to the treatment group will receive the FloStent implant during this procedure, while those in the control group will have the cystoscopy without the implant deployment, serving as a sham treatment. The study is randomized, double-blind, and includes parallel groups to compare outcomes over time. Throughout the study, participants will be assessed on changes in their International Prostate Symptom Score IPSS over 12 months. Researchers will monitor symptom improvements at 3, 6, and 12 months to evaluate response rates. Participants will complete study visits and follow the protocol to help researchers gather data on the devices safety and impact on urinary symptoms.

Age: 45Years +MALEPhase Not Applicable
20 locations
P

Actively Recruiting

Healthy Volunteer

This research evaluates the PureWick Urine Collection System as a non-invasive way to manage nocturia in women aged 50 and older. Nocturia, which involves waking at night to urinate, is common in older adults and increases the risk of falls and fractures. The study aims to assess whether using PureWick can reduce nighttime bathroom trips and improve sleep quality and overall life quality. Participants use the PureWick System, which includes an external catheter, tubing, and a collection canister. The device allows urine collection while remaining in bed, potentially lowering fall risk. The study is a single-group pilot conducted at one center, with follow-up lasting up to 3 months to observe urinary and sleep outcomes, as well as any related adverse events. During the study, participants are monitored for changes in the number of nocturia episodes, sleep quality via questionnaires, and other health factors such as urinary tract infections and skin condition. Data is collected at the start and after 3 months of device use. Researchers will measure how many patients achieve a 50% or greater reduction in nighttime urination, along with quality-of-life improvements and safety outcomes.

Age: 50Years +FEMALEPhase Not Applicable
2 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of Tradipitant on treating nausea and vomiting caused by GLP-1 receptor agonist use in adults who are overweight or have class I or II obesity. This phase 3, randomized, placebo-controlled study includes healthy volunteers without serious medical issues or diabetes. The goal is to better understand how Tradipitant impacts these symptoms compared to a placebo. Participants will be randomly assigned to receive either Tradipitant or a placebo, both given as oral capsules twice daily for about two weeks. The study has two treatment arms one receiving Tradipitant and the other receiving a placebo. The study uses quadruple masking to ensure unbiased results. During the study, participants will record nausea and vomiting symptoms daily in a symptom diary. Researchers will measure the proportion of participants experiencing vomiting episodes and assess nausea severity over one week. The study will monitor safety and side effects throughout, with the total participation duration around two weeks of treatment.

Age: 18Years - 65YearsAll GendersPhase 3
10 locations
O

Actively Recruiting

Healthy Volunteer

Researchers are conducting a non-interventional, multi-site observational study to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product. This product is applied following various medical aesthetic procedures to assess its effects on post-procedural erythema and recovery. The study is open-label and involves participants aged 18 to 60 undergoing specific aesthetic treatments. Participants plan to use the Acorn Autologous Hair Follicle Secretome cosmetic product as an adjunct after medical aesthetic procedures such as laser resurfacing ablative or non-ablative, Tixel treatment of the face, and treatment of acne or surgical scars combined with other procedures like microneedling or ablative laser. Some scalp treatments and Ellacor procedures are closed to enrollment. The study does not involve any experimental interventions but observes the real-world application of this topical product. During the study, participants will be monitored for symptoms and downtime after their procedures using questionnaires over 1 to 7 days post-treatment. Researchers will collect data on post-procedure symptoms and recovery time to evaluate the products impact. The total study period extends until February 2027, with ongoing assessments at specified intervals to capture real-world outcomes and safety information.

Age: 18Years +All Genders
42 locations
M

Actively Recruiting

Researchers are evaluating the effects of two types of amnion graftsa tri-layer and a single-layer membrane wrapon hard-to-heal diabetic foot ulcers DFUs and venous leg ulcers VLUs. This multicenter hybrid platform trial compares these interventions to a matched retrospective control group receiving standard care. The study aims to gather real-world evidence to better understand how these treatments perform in everyday clinical settings across a diverse patient population. Participants are randomly assigned to receive either the BioLab Membrane Wrap Lite, a single-layer human amnion graft, or the BioLab Tri-Membrane Wrap, a triple-layer graft containing amnion and chorion layers. Both grafts are used alongside standard care, which includes debridement, moisture balance maintenance, bacterial reduction, offloading, and compression. The control group consists of matched patients from a large wound registry receiving standard care alone. During the study, participants will be monitored for wound healing progress, with the primary outcome being wound closure at 12 weeks. Secondary outcomes include wound area reduction at 4, 8, and 12 weeks. The study involves regular visits to assess wound size and healing status. This research helps evaluate the potential benefits of adding amnion grafts to standard wound care over a 12-week period.

Age: 18Years +All GendersPhase Not Applicable
7 locations
L

Actively Recruiting

Researchers are evaluating the long-term outcomes of teplizumab treatment in people with Stage 2 Type 1 Diabetes T1D to see if it delays the onset of Stage 3 T1D. This observational, prospective cohort study will monitor participants who receive teplizumab as part of their usual clinical care across multiple sites. The study also assesses patient-reported outcomes to understand the emotional and psychosocial impact of T1D and its treatment. Participants treated with teplizumab in routine care will be followed for up to 10 years, depending on when they start the study after their initial infusion. The study does not provide any treatments but observes how teplizumab is used in real-world practice. It will track various health measures, including glycemic control, adverse events, diabetes-related complications, and quality of life changes over time. Throughout the study, participants will have assessments to measure blood sugar control using different tests and devices, report any adverse events, and complete questionnaires about their emotional well-being. Researchers will measure the time from the start of teplizumab infusion to the development of Stage 3 T1D and monitor hospital visits related to diabetes. The total study duration for each participant may last up to 10 years, offering a detailed view of teplizumabs effects in everyday clinical settings.

All AgesAll Genders
10 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the iTind device compared to the UroLift system for men experiencing lower urinary tract symptoms caused by benign prostatic hyperplasia BPH. Both devices offer minimally invasive treatment options, with iTind being a temporary implant that reshapes the urethra over 5 to 7 days, while UroLift involves permanent implants to widen the urethral opening. This study aims to directly compare these two methods to better understand their benefits and safety profiles. Participants are randomly assigned to receive either the iTind device, which is temporarily placed for 5 to 7 days, or the UroLift system, which places permanent implants in the prostate. The study evaluates changes in urinary symptoms and quality of life over several months, with follow-up assessments extending up to 36 months. Researchers monitor adverse events related to the procedure or devices and compare the need for additional interventions between the two groups. During the study, participants will complete questionnaires and undergo evaluations at baseline and multiple follow-up visits up to three years. Key measurements include the International Prostate Symptom Score IPSS to assess urinary symptoms and quality of life scores. Safety is closely monitored throughout the first three months post-procedure, and longer-term outcomes like symptom improvement and device-related events are tracked over time. Overall participation may last several years to gather comprehensive data on both treatments.

Age: 50Years +MALEPhase Not Applicable
19 locations
R

Actively Recruiting

This research aims to collect detailed information on how the Zenflow Spring System, a minimally invasive device treatment, works for men with lower urinary tract symptoms LUTS associated with benign prostatic hyperplasia BPH. The registry tracks the devices performance during the implant procedure and follows participants over time to assess symptom improvement and patient satisfaction. Participants will undergo treatment with the Zenflow Spring System as per the approved instructions for use. The study observes the devices effects during implantation and monitors outcomes through scheduled follow-up visits at 1, 3, 6, and 12 months after the procedure. During the study, participants will have their symptoms, activity recovery, and any side effects or problems related to the device evaluated at these follow-up visits. Researchers will measure effectiveness using the International Prostate Symptom Score IPSS and monitor safety by recording adverse events from baseline through 12 months. The total participation period includes the implantation and one-year follow-up.

Age: 18Years +MALE
8 locations
P

Actively Recruiting

Researchers are evaluating whether TR987 0.1% gel combined with Standard of Care is more effective than Standard of Care alone for treating Venous Leg Ulcers VLUs. This Phase 3, outpatient, randomized, double-blind study focuses on participants with non-healing VLUs to assess the drugs efficacy and safety over 16 weeks. Participants are assigned to one of two groups one receiving TR987 0.1% gel plus Standard of Care, and the other receiving Standard of Care alone. The gel is applied topically twice weekly for the first four weeks, then weekly for the remaining 12 weeks. Standard of Care includes wound cleansing, dressings, and compression bandaging throughout the treatment period. During the study, participants will be regularly assessed for ulcer closure, pain levels, and changes in ulcer size at 12 and 16 weeks. The primary measure is the proportion of participants with complete ulcer closure by Week 16. Secondary outcomes include sustained closure at 3 months, pain reduction, and significant ulcer size reduction. Safety and tolerability are also monitored throughout the study period.

Age: 18Years +All GendersPhase 3
33 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate whether Urolift, a minimally invasive procedure, can reduce urinary side effects caused by stereotactic body radiation therapy SBRT in male patients with benign prostatic hyperplasia BPH and prostate cancer. These side effects include increased urinary frequency, pain during urination, and nighttime urination. Urolift is already a standard treatment for BPH, designed to keep the prostatic urethra open by placing a stainless-steel implant. Participants will receive a one-time Urolift procedure before starting SBRT for prostate cancer. Urolift involves placing end pieces on both sides of the prostatic urethra to maintain an open urinary channel. The study involves only one group and includes one year of follow-up after treatment to assess urinary symptoms and quality of life. During the study, participants will complete questionnaires to measure urinary symptoms and quality of life over an average of one year. Researchers will track changes in urinary symptom scores, sexual function, pain levels, overactive bladder symptoms, and overall health quality. Medication use for urinary symptoms will also be monitored. The study is led by Northwell Health and lasts until March 2028.

Age: 50Years - 99YearsMALEPhase Not Applicable
1 location